UMIN ID: UMIN000001487
Registered date:07/11/2008
A phase II study of gemcitabine in pancreatic endocrine tumor
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | pancreatic endocrine tumor |
| Date of first enrollment | 2004/11/01 |
| Target sample size | 18 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | gemcitabine |
Outcome(s)
| Primary Outcome | response rate |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1) Intestinal pneumonia or lung fibrosis 2) Massive pleural or abdominal effusion 3) Symptomatic brain metastasis 4) History of other active malignancy 5) Severe infection 6) Severe complication 7) Pregnancy or the desire to preserve fecundity 8) uncontrollable endocrine symptom 9) Inadequate physical condition, as diagnosed by primary physician |
Related Information
| Primary Sponsor | National Cancer Center Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Ministry of Health, Labor and Welfare |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Chigusa Morizane |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Japan |
| Telephone | |
| Affiliation | National Cancer Center Hospital Hepatobiliary and Pancreatic Oncology Division |
| scientific contact | |
| Name | Chigusa Morizane |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Japan |
| Telephone | 03-3542-2511 |
| Affiliation | National Cancer Center Hospital Hepatobiliary and Pancreatic Oncology Division |